Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients

Am J Hematol. 2017 Feb;92(2):E15-E17. doi: 10.1002/ajh.24599.

Authors

John C Reneau¹, Dennis Asante², Holly van Houten^{3

4}, Lindsey R Sangaralingham³, Francis K Buadi⁵, Amir Lerman⁶, Joerg Herrmann⁶

Affiliations

¹ Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
² Department of Health Sciences Research, Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
³ Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota.
⁴ OptumLabs, Cambridge, Massachusetts.
⁵ Division of Hematology, Mayo Clinic, Rochester, Minnesota.
⁶ Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.

PMID: 27813147
DOI: 10.1002/ajh.24599

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bortezomib / adverse effects*
Bortezomib / therapeutic use
Cardiotoxicity
Heart Diseases / epidemiology*
Heart Diseases / etiology*
Heart Diseases / mortality
Humans
Kaplan-Meier Estimate
Lenalidomide
Multiple Myeloma / complications*
Multiple Myeloma / drug therapy
Multiple Myeloma / mortality
Propensity Score
Proportional Hazards Models
Risk
Thalidomide / adverse effects
Thalidomide / analogs & derivatives*
Thalidomide / therapeutic use

Substances

Antineoplastic Agents
Thalidomide
Bortezomib
Lenalidomide